immunotherapy

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF),…

1 year ago

Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of…

1 year ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Media Release A total of 171 head and neck squamous cell carcinoma (HNSCC) patients enrolled in randomised, multicentre Phase IIb…

1 year ago

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Initial survival data from phase 2 clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) showed survival supportive…

1 year ago

Angle PLC Announces Launch of PD-L1 Test to Support Cancer Studies

ANGLE LAUNCHES PD-L1 TEST TO SUPPORT CANCER THERAPY STUDIESANGLE's Portrait PD-L1 test uses CTCs harvested from the Parsortix system to…

1 year ago

Former Amryt Pharma Leadership Team join Poolbeg

Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg PharmaPoolbeg team boosted by highly experienced executives with track…

1 year ago

AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer

Data presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment…

1 year ago

Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program

Third annual BioTech Breakthrough Award recognizes excellence in life science and biotechnology solutions, services and companies GC012F, a FasTCAR-enabled autologous…

1 year ago

IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023

LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…

1 year ago